SlideShare a Scribd company logo
1 of 82
DENGUE
EPIDEMIOLOGY
Dr SEEMA VERMA
Department of Community medicine
PGIMS Rohtak
Haryana INDIA
DENGUE EPIDEMIOLOGY
Introduction
Epidemiological determinants
Case definition
Diagnosis and treatment
Prevention and control
Recent update & myths
DENGUE EPIDEMIOLOGY
Introduction
Epidemiological determinants
Case definition
Diagnosis and treatment
Prevention and control
Recent update & myths
INTRODUCTION
 Most rapidly spreading mosquito-borne viral
disease in the world.
 The infection causes flu-like illness,
⚫ and occasionally develops into a potentially lethal
complication – dengue shock syndrome.
 Incidence of dengue has grown dramatically
around the world in recent decades.
 There is under-reporting & misclassification.
INTRODUCTION
 Before 1970, only 9 countries had experienced
severe dengue epidemics.
 Disease now endemic in more than 100 countries
in the WHO regions of Africa, the Americas, the
Eastern Mediterranean, South-East Asia and the
Western Pacific.
 The America, South-East Asia and Western
Pacific regions are the most seriously affected.
INTRODUCTION
 Recent estimate –
⚫ 390 million dengue infections / year.
⚫ 96 million manifest clinically
 The number of cases reported increased from 2.2
million in 2010 to 3.2 million in 2015.
 Sharp increase in the number of cases reported in
recent years.
*World Health Organization. Dengue and severe dengue fact sheet. Geneva: WHO; 2016
INTRODUCTION
 South-East Asia region – divided into 3 categories
• (Bangladesh,India, Indonesia,Maldives,Myanm
ar,Sri Lanka,ThailandandTimor-Leste)
• Majorpublichealthproblem;
• Leadingcauseof hospitalizationanddeath
amongchildren;
• Hyperendemicity withall4serotypescirculating
in urbanareas;and
• Spreadingtoruralareas
A
INTRODUCTION
 South-East Asia region – divided into 3 categories
• (Bhutan,Nepal)
• Endemicityuncertain;
• Bhutanreportedfirst outbreakin2004;and
• Nepalreported firstindigenouscasein2004.
B
• (DPRKorea)
• Noevidenceofendemicity.
C
INTRODUCTION
INTRODUCTION
 Dengue now endemic in all states/UTs. After
1996, outbreaks upsurge recorded in 2003, 2005,
2008, 2010, 2012 and 2013.
 During 2014, more than 40,000 cases and 137
deaths reported & case fatality rate 0.33%.
 In 2015, 90,000 cases and 181 deaths reported.
*DK Taneja’s Health Policies Programmes in India; 15th ed. 2017
INTRODUCTION
 In 2015, Delhi, recorded its worst outbreak since
2006 with over 15000 cases.
 Disease is spreading to newer geographical areas
every year.
 Outbreaks have been reported from rural areas of
Haryana, Maharashtra and Karnataka.
*DK Taneja’s Health Policies Programmes in India; 15th ed. 2017
INTRODUCTION (CASE TREND)
140000
120000
100000
80000
60000
40000
20000
0
200820092010 2011 201220132014201520162017
HARYANA
INDIA
DENGUE
CASES
YEAR
CASES TILL 8TH OCTOBER 2017 (NVBDCP)
129161
78691
99913
75808
40571
INTRODUCTION (MORTALITY TREND)
50
0
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
100
150
300
250
200
INDIA
HARYANA
DEATHS
YEAR
DATATILL 8TH OCTOBER 2017 (NVBDCP)
INTRODUCTION
 Dengue Problem Statement: ROHTAK 2017
*Till 15th Oct 2017
INTRODUCTION
 Dengue Problem Statement: Haryana & Rohtak
2017
800
600
400
200
0 Haryana
Rohtak
Rohtak
Haryana
187
628
*TILL 15TH OCTOBER 2017
1
0
INTRODUCTION
DENGUE EPIDEMIOLOGY
Introduction
Epidemiological determinants
Case definition
Diagnosis and treatment
Prevention and control
Recent update & myths
EPIDEMIOLOGICAL DETERMINANTS
Agent
Host
Environment
AGENT: DENGUE VIRUS
 Arbovirus ss RNA virus
⚫ Genus Flavivirus
⚫ Family Flaviviraede.
 Four serotypes:
⚫ DENV-1, DENV-2, DENV-3 and DENV-4.
 Infection with one serotype confers
⚫ life long immunity to that virus serotype
⚫ and only for few months to other serotypes.
AGENT: DENGUE VIRUS
 All 4 serotypes are capable to produce DHF.
 However, severity of the disease ascertained by
⚫ Serotype sequence & the strain which produces the
secondary inf
 DENV-1 DENV-2
 DENV-3  DENV-2
 DENV-4  DENV-2
- 500 fold
- 150 fold
- 50 fold
risk of DHF
risk of DHF.
AGENT: DENGUE VIRUS
WHY SECOND INFECTION IS
MORE DANGEROUS??
SENSITIZATION
OF IMMUNE
SYSTEM
PATIENT
FIRST
INFECTION
SECOND INFECTION WITH
DIFFERENT SEROTYPE
IMMUNOLOGICAL
CATASTROPHY
VECTOR
A aegypti is prevalent transmitter throughout India
except Kerla where A albopictus is main vector for transmission.
AEDES MOSQUITO
 A small (5mm), black mosquito with white
stripes.
 Adult life span:15 days,
 Flight range – 400 meters (average).
AEDES MOSQUITO
FEEDING HABITS:
 Usually a Day biter,
 preferably bites on the ankles and elbows.
⚫ (Peak : within 2 hours after dawn and before
sunset.)
 Is strongly anthropophilic.
 Known to be a nervous feeder
⚫ it bites more than one host to complete one meal.
⚫ This feeding habit results in the generation of
multiple cases and the clustering of dengue cases
in the cities.
AEDES MOSQUITO
Life cycle: 7 – 10 days
ENVIRONMENTAL FACTORS
 The population of Aedes aegypti fluctuates with
rainfall and water storage.
 Its life span is influenced by
⚫ temperature (160C -300C) and humidity (60-80 %).
 Even with a 20 increase in temperature,
⚫ The extrinsic incubation period of DENV will be
shortened
⚫ and more infected mosquitoes are available for a
longer duration.
K Park , 24th ed; 2017,p 262
ENVIRONMENTAL FACTORS
 Unplanned urbanization raises the potential for
the vector to breed at high level
 Rural spread of the vector is a relatively recent
occurrence with lifestyle changes coupled with
development activities, improved transport
system, deficient water management including
improper water storage practices.
BREEDING PLACES
ENVIRONMENTAL FACTORS
 Seasonal trends of dengue cases in India 2010-
2013
ENVIRONMENTAL FACTORS
140
120
100
80
60
40
20
0
 Seasonal trends of dengue cases in Rohtak 2017
cases
july aug sep oct
cases
CASES
MONTHS
*TILL OCTOBER 15TH 2017
TRANSMISSION OF DISEASE
 The Aedes mosquito becomes infective by feeding on a
patient from the day before onset to the 5th day (viraemia
stage) of illness.
 After an extrinsic incubation period of 8 to 10 days, the
mosquito becomes infective, and is able to transmit the
infection.
 Once the mosquito becomes infective, it remains so for
life.
 The genital tract of the mosquito gets infected and
transovarian transmission of dengue virus occur.
K.Parks.Park’s Textbook of Preventive and social medicine. Epidemiology of communicable
diseases.24rd edition.Jabalpur india:M/s Banaridas Bhanot;2017:page-264
TRANSMISSION OF DISEASE
DENGUE EPIDEMIOLOGY
Introduction
Epidemiological determinants
Case definition
Diagnosis and treatment
Prevention and control
Recent update & myths
CASE DEFINITION
 Suspected:
⚫ A case compatible with the clinical description.
 Probable:
⚫ A case compatible with the clinical description with
one or more of the following:
⚫ Supportive serology.
⚫ Occurrence at same location and time as other
confirmed cases of dengue fever.
 Confirmed:
⚫ A case compatible with the clinical description that is
laboratory confirmed.
D
S
S
CLASSIFICATION
Dengue
virus
infection
Asymtomatic
“ICE BERRG”
Symptomatic
Undifferentiated
fever{ viral
syndrome}
Dengue fever
Without
haemorrhage
With unusual
haemorrhage
Dengue
haemorrhagic
fever
Unusual
manifestation/
expanded dengue
syndrome
DHF 1
DHF 2
DHF3
DHF4
DSS
CLASSICAL DENGUE FEVER
DENGUE HAEMORRHAGIC FEVER
(DHF)
 A severe form of dengue fever.
 The course of dengue illness can be divided into
three phases-
⚫ febrile phase,
⚫ critical phase and
⚫ recovery phase,
FEBRILE PHASE
 Day 1 – 4
 Fever with Positive tourniquet test
TOURNIQUET TEST
Goal of the test :-
 Toasses fragility of capillary walls
 Toidentify thrombocytopenia
 In DHF grade 1, a positive
tourniquet test serves as the only
indicator of haemorrhagic tendency
• ≥20 petechiae
per 1 square
inch.
CRITICAL / HAEORRHAGIC PHASE
 Whenthetemperaturedrops to37.5-38°Cor
less,andremainsbelowthis level, usuallyon days4-
7ofillness,
 Anincreasein capillary permeability in parallel with
increasing haematocritlevels mayoccur.
 This marksthebeginning ofthecritical phase.
 Theperiodofclinicallysignificant plasmaleakage
usuallylasts 24-48 hours.
CRITICAL / HAEORRHAGIC PHASE
 Shock occurs when a critical volume of
plasma is lost through leakage.
 It is often preceded by warning signs of
⚫ Abdominal pain or tenderness,
⚫ Persistent vomiting,
⚫ Clinical fluid accumulation,
⚫ Mucosal bleeding,
⚫ Lethargy,
⚫ Restlessness,
⚫ Liver enlargement more than 2 cm. and
⚫ Oliguria.
CRITICAL / HAEORRHAGIC PHASE
 With prolonged shock, the consequent organ
hypoperfusion results in progressive organ
impairment, metabolic acidosis and disseminated
intravascular coagulation.
 This in turn leads to severe haemorrhage causing the
haematocrit to decrease in severe shock. Instead of the
leukopenia usually seen during this phase of dengue, the
total white cell count may increase in patients with severe
bleeding.
 In addition, severe organ impairment such as severe
hepatitis, encephalitis or myocarditis and/or severe
bleeding may also develop without obvious plasma leakage
or shock.
RECOVERY PHASE
 After critical phase, 48-72 hours of reabsorption
of extravascular fluid
 Well-being, appetite improves
 Bradycardia common
 Hemodynamic status improves
 GI symptoms abate
 Blood counts normalize (RBC>WBC>Plt)
 Diuresis occurs
 Prolonged convalescence
DENGUE EPIDEMIOLOGY
Introduction
Epidemiological determinants
Case definition
Diagnosis and treatment
Prevention and control
Recent update & myths
RECOMMENDED TESTS
 GOI recommends use of ELISA based antigen
detection test (NS1) for diagnosing the cases
from 1st day onwards.
 Antibody detection test IgM Capture ELISA
(MAC ELISA) for diagnosing the cases after
5th day of onset of disease for confirmation of
Dengue infection
RECOMMENDED TESTS
 NVBDCP had been using MAC- ELISA for
diagnosis of dengue infection in the network of
Diagnostic Centers established/ identified in the
Sentinel Surveillance Hospitals (SSHs) and
Apex Referral Laboratories (ARLs) across
the country.
RECOMMENDED TESTS
IgG (FIRST)
IgG (SECOND)
IgM
NS-1
VIRUS
RAPID TEST COMBO KIT
 Most of the studies have
shown that detection of
both the NS1 Antigen
and the anti-dengueIgm
together yields
satisfactory clinical
results, instead of sole
NS1 antigen detection.
DIAGNOSTIC KIT USED IN PGIMS
ROHTAK
For NS-1 Antigen detection ( <5days)
DIAGNOSTIC KIT USED IN PGIMS
ROHTAK
IgM capture ELISA ( >5days)
SENTINAL SURVEILLANCE HOSPITALS FOR DENGUE IN HARYANA
2016
1 B.K. Hospital, Faridabad
2 General Hospital, Ambala
3 State Bacteriological Laboratory,Karnal
4 General Hospital, Gurgaon
5 General Hospital, Panchkula
6 Medical College, Agroha
7 Civil Hospital, Hissar
8 PGIMS,Rohtak
9 District Hospital, Kaithal
10 District Hospital, Kurukshetra
11 Mukandi lal Hospital,Yamuna Nagar
12 Civil Hospital, Sonipat
13 General Hospital, Palwal
14 Civil Hospital, Bahadurgarh (Jhajjar)
15 District Hospital, Sirsa
16 District Hospital, Bhiwani
17 District Hospital, Fatehbaad
18 District Hospital, Jind
19 District Hospital, Panipat
20 Civil Hospital, Mandi Khera (Mewat)
21 Civil Hospital, Narnual
22 Civil Hospital, Rewari
APEX REFERAL LABORATORIES
National Institute of Virology (ICMR), Pune
2. National Center for Disease Control (former NICD), Delhi
3. National Institute of Mental Health & Neuro-Sciences, Bangalore
4. Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow
5. Post- Graduate Institute of Medical Sciences(PGIMER), ICMR, Chandigarh
6. All India Institute of Medical Sciences, Delhi
7. ICMR Virus Unit, National Institute of Cholera & Enteric Diseases, Kolkata.
8. Regional Medical Research Centre, (ICMR),Dibrugarh, Assam
9. King’s Institute of Preventive Medicine (ICMR), Chennai
10. Institute of Preventive Medicine, Hyderabad
11. B J Medical College (ICMR) , Ahmedabad
12. State Public Health Laboratory, Thiruvananthapuram, Kerala
13. Defence Research Development and Establishment, Gwalior, Madhya Pradesh
14. Nati onal Institute for Research in Tribal Health (NIRTH) (Former
RMRCT), ICMR, Jabalpur, Madhya Pradesh
15. Regional Medical Research Centre, (ICMR), Bhubaneswar, Odisha
16. Andhra Medical College, Visakhapatnam
MANAGEMENT OF DENGUE FEVER
MANAGED AT HOME
BED REST
COLD/TEPID SPONGING
PARACETAMOL
WARNING SIGNS SHOULD BE EXPLAINED
ADVISED TO REPORT TO HOSPITAL IF WARNING
SIGNS APPEAR
WARNING SIGNS
RECURRET VOMITING
BLEEDING FROM DIFFERENT SITES:
 GUM BLEEDING
 BLOOD IN SPUTUM
 BLOOD IN VOMIT OR STOOL
 INCREASED MENSTRUAL FLOW
ABDOMINAL PAIN OR DISCOMFORT
COLD CLAMY SKIN
PALPITAION BREATHLESSNESS
MANAGEMENT OF DHF
ALL CASES TO BE ADMITTED
ENCOURAGE ORAL FLUIDS:ORS,JUICES
START I.V. FLUIDS
PARACETAMOL
DAILY HEMATOCRIT DETERMINATION
MONITOR URINE OUTPUT, B.P. AND OTHER VITAL SIGNS
Platelet concentrate :
 if the platelet count is < 50,000 / mm3 with bleeding.
 In the absence of bleeding :counts <10,000/ mm3
MANAGEMENT OF DSS
All of the following 6 criteria must be met before a
patient is discharged from the hospital :
1. Visible improvement in clinical picture
2.Absence of fever for 24 hours & return of appetite
3.Three days after recovery from shock
4.Stable hematocrit
5.Platelet count greater than 50,000/mm3 and rising
6.No respiratory distress
DENGUE EPIDEMIOLOGY
Introduction
Epidemiological determinants
Case definition
Diagnosis and treatment
Prevention and control
Recent update & myths
GLOBAL STRATEGY FOR
DENGUE
PREVENTION AND CONTROL, 2012–2020
 GOAL: To reduce the burden of dengue
 OBJECTIVES: (using 2010 as the baseline).
 To reduce mortality from dengue by at least
50% by 2020.
 To reduce morbidity from dengue by at least
25% by 2020
 To estimate the true burden of dengue till
2015.
WHO (2012), Global Strategy for Dengue Prevention and Control,2012-2020.
EPIDEMIOLOGICAL SURVEILLANCE
Routine surveillance:
 Passive
 Active
Proactive surveillance:
 serological surveillance designed to monitor
dengue virus transmission, especially during
inter-epidemic periods and provide information
on:
⚫ Where transmission is occurring,
⚫ What virus serotype or serotypes are involved and
⚫ Which type of illness is associated with the dengue
EPIDEMIOLOGICAL SURVEILLANCE
Reporting :
 During transmission period
⚫ (monsoon and post Monsoon reporting will be on
⚫ daily basis by email or by fax.
 In non or low transmission period
⚫ reporting will be on weekly basis.
⚫ Report of the previous week (Monday to Saturday)
should be compiled by the States and send to
NVBDCP by every Monday.
EPIDEMIOLOGICAL SURVEILLANCE
EPIDEMIOLOGICAL SURVEILLANCE
The larval indices used to determine the intensity
of dengue vector are:
 House Index:
⚫ Percentage of houses positive for larvae of A aegypti
⚫ (> 10% - high risk of transmission)
 Breteau Index:
⚫ Number of positive containers for A aegypti larvae
per 100 houses.
⚫ (> 50% - high risk of transmission)
ENVIRONMENTAL CONTROL
 Don’t allow water to remain stagnant
in and around your house.
 Fill the ditches.
 Clean the blocked drains.
 Empty the room air coolers and flower vases completely
at least once in seven days and let them dry.
 Dispose off old containers, tins and tyres etc. properly.
 Keep the water tanks and water containers tightly
covered so that the mosquitoes can not enter them and
start breeding.
ENVIRONMENTAL CONTROL
 Wherever it is not possible to completely drain the water
off from room cooler, water tanks etc., it is advised to put
about two tablespoons (30 ml.) of petrol or kerosene
oil into them for each 100 litres of water.
 This will prevent mosquito breeding.
 Repeat it every week.
 Keep the surroundings of your house clean.
 Don’t allow wild herbs etc. to grow around
your house. They act as hiding and resting
places for mosquitoes.
PERSONAL PROTECTION MEASURES
Protective clothing mats
coils
Insecticide treated nets
Permethrin treated clothing
Repellent sprays
(DEET)
Electric Raquete
CHEMICAL CONTROL
LARVICIDAL
ADULTICIDAL
RESIDUAL TREATMENT
SPACE SPRAY
OUTDOOR
INDOOR
COLD AEROSOL
THERMAL FOGGING
PYRETHRUM
INDOOR SPACE SPRAYING
 Commercial formulation of 2% pyrethrum
(deltamethrin) extract is diluted with kerosene
in the ratio one part of 2% pyrethrum extract
with 19 parts of kerosene (volume/volume).
 One liter of ‘formulation is sufficient to cover
20 households, each household having 100
cubic meters of indoor space.
OUTDOOR SPACE SPRAYING
 Usually carried out in early morning or late afternoon
 For narrow roads: the spray should be directed backwards
from the vehicle.
 For wide roads: the spray should be directed at a right angle
(downward) to the road.
1. Ultra Low Volume (ULV) Spray(cold fog):
⚫ Malathion TECHNICAL is the insecticide used for this
purpose.
⚫ Remain suspended in air and driven under the influence of
wind.
⚫ Since no diluent is used, the technique is more cost-
effective than thermal fogging.
⚫ But it does not generate a visible fog.
OUTDOOR SPACE SPRAYING
2. Thermal Fogging
⚫ Water based
⚫ Oil based(m/c used)
 Technique is based on the principle that
insecticide is vaporized, which condenses to
form a fine cloud of droplets on contact with
cooler air when it comes out of the machine.
 Insecticide of choice for fogging is
malathion/pyrethrin.
LARVICIDES
 Cycle : 2-3rounds /year
 Both internal and external walls of container should
be sprayed and up to 60cm of height.
LARVICIDES
FOR POTABLE WATER FOR NON-POTABLE WATER
TEMEPHOS (1mg/L)
METHOPRENE(1mg/l)
TEMEPHOS (1mg/L)
Bacillus thuringiensis israelensis
(bio-chemical)
BIOLOGICAL CONTROL
Larvivorous Fish
 Advantages
 Environmental friendly
 Easy to introduce
 Self propagating & self sustainable
 User friendly
 Helps build community participation &
intersectoral collaboration
 Cost-Effective - no recurrent costs
Gambusia affinis
Lebister reticularis
BIOLOGICAL CONTROL
Larvivorous Fish
 Limitations
 Extremes of temperatures and pollution
 Suitable for some types of breeding sources only
 Needs proper planning with mapping of
breeding sources & promotional efforts
Biolarvicide:
Bacillus thuringiensis iserailensis (Bti)-Endotoxin
: 2.5% suspension, 1 lit/50 m2, once every 2
Aphanius dispar
4s
VECTOR CONTROL
SEARCH AND DESTROY
SELF-PROTECTION
MEASURES
SEEK EARLY CONSULTATION
SAY NO TO INDISCRIMINATE
FOGGING
 HEALTH EDUCATION
🞭 Impart knowledge to common people regarding the
disease and vector through various media sources like T.v.,
Radio,Cinema slides, PAMPLETS etc.
 COMMUNITY
PARTICIPATION
Sensitizing and involving the community for
detection of Aedes breeding places and their
elimination
LEGISLATION
1. Model civic byelaws: fine/punishment is imparted, if
breeding is detected. In cities
Rohtak, Delhi, Mumbai, Chandigarh.
2. Building Construction Regulation Act: In
Mumbai, prior to any construction activity, the
owners/builders deposit a fee for controlling
mosquitogenic conditions at site by the Municipal
Corporation.
3. Environmental Health Act
4. Health Impact Assessments
OUTBREAK RESPONSE
Rapid response team:
 Aim to undertake urgent epidemiological investigations
and provide on the spot technical guidance required and
logistic support.
Rapid response team: Rohtak
 District malaria officer
 D.F.W.O
 SMO
 Epidemiologist
 MO CH (Med)
 MO CH (Micro)
DENGUE EPIDEMIOLOGY
Introduction
Epidemiological determinants
Case definition
Diagnosis and treatment
Prevention and control
Recent update & myths
DENGUE VACCINE
 Currently, there is no vaccine available in India
to protect against dengue.
 In recent years the development of dengue
vaccines has accelerated dramatically.
 Today, several vaccines are in various stages of
advanced development, with clinical trials
currently underway on five candidate vaccines.
http://www.denguevaccines.org/why-a-vaccine
http://www.denguevaccines.org/why-a-vaccine
A live, attenuated, tetravalent dengue
vaccine (CYD-TDV) candidate, containing
four recombinant dengue viruses (CYD1- 4)
 The fifth variant DENV-5 has been isolated in October
2013.
 The likely cause of emergence of the new serotype could
be genetic recombination, natural selection.
 GM (Genetically modified Mosquito) – Male sterile
mosquitoes are released in environment so as to mate
with wild females and produce sterile eggs. It is still in
experimental stage.
http://nvbdcp.gov.in/Doc/Dengue-FAQ-2015.pdf
Spread the dengue prevention
message to others…
Let your
family, friends and
neighbours know
about the dangers of
breeding Mozzies!!
THANK YOU …

More Related Content

Similar to dengueepidemiology-200501161658.....pptx

Journal of-general-medicine
Journal of-general-medicine Journal of-general-medicine
Journal of-general-medicine kalpita Raut
 
Diagnosis and management of dengue in children (IAP Infectious Diseases Chapter)
Diagnosis and management of dengue in children (IAP Infectious Diseases Chapter)Diagnosis and management of dengue in children (IAP Infectious Diseases Chapter)
Diagnosis and management of dengue in children (IAP Infectious Diseases Chapter)Dr Padmesh Vadakepat
 
Biology CBSE class 12th investigatory project
Biology CBSE class 12th investigatory projectBiology CBSE class 12th investigatory project
Biology CBSE class 12th investigatory projectVishvjeet Yadav
 
Dengue, Malaria, Chikungunya, Japanese Encephalitis, Pest Control.pptx
Dengue, Malaria, Chikungunya, Japanese Encephalitis, Pest Control.pptxDengue, Malaria, Chikungunya, Japanese Encephalitis, Pest Control.pptx
Dengue, Malaria, Chikungunya, Japanese Encephalitis, Pest Control.pptxYuvethaIndran
 
The dengue syndrome_Vighnesh D
The dengue syndrome_Vighnesh DThe dengue syndrome_Vighnesh D
The dengue syndrome_Vighnesh DVighnesh D
 
Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...
Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...
Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...Arun Vasireddy
 

Similar to dengueepidemiology-200501161658.....pptx (20)

Dengue
DengueDengue
Dengue
 
Dengue
DengueDengue
Dengue
 
Dengue
Dengue Dengue
Dengue
 
Journal of-general-medicine
Journal of-general-medicine Journal of-general-medicine
Journal of-general-medicine
 
Diagnosis and management of dengue in children (IAP Infectious Diseases Chapter)
Diagnosis and management of dengue in children (IAP Infectious Diseases Chapter)Diagnosis and management of dengue in children (IAP Infectious Diseases Chapter)
Diagnosis and management of dengue in children (IAP Infectious Diseases Chapter)
 
Degue fever
Degue feverDegue fever
Degue fever
 
Chikhungunya
ChikhungunyaChikhungunya
Chikhungunya
 
Biology CBSE class 12th investigatory project
Biology CBSE class 12th investigatory projectBiology CBSE class 12th investigatory project
Biology CBSE class 12th investigatory project
 
DENGUE.pptx
DENGUE.pptxDENGUE.pptx
DENGUE.pptx
 
Ebola
EbolaEbola
Ebola
 
Dengue
DengueDengue
Dengue
 
Dengue, Malaria, Chikungunya, Japanese Encephalitis, Pest Control.pptx
Dengue, Malaria, Chikungunya, Japanese Encephalitis, Pest Control.pptxDengue, Malaria, Chikungunya, Japanese Encephalitis, Pest Control.pptx
Dengue, Malaria, Chikungunya, Japanese Encephalitis, Pest Control.pptx
 
Dengue
DengueDengue
Dengue
 
The dengue syndrome_Vighnesh D
The dengue syndrome_Vighnesh DThe dengue syndrome_Vighnesh D
The dengue syndrome_Vighnesh D
 
dengue fever management
dengue fever management  dengue fever management
dengue fever management
 
Dengue2
Dengue2Dengue2
Dengue2
 
Arboviruses in indonesia
Arboviruses in indonesiaArboviruses in indonesia
Arboviruses in indonesia
 
Dengue fever
Dengue fever Dengue fever
Dengue fever
 
Dengue Fever
Dengue FeverDengue Fever
Dengue Fever
 
Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...
Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...
Dengue fever Epidemiology - pathogenesis - symptoms - diagnosis - Management ...
 

More from DebdattaMandal5

Body fluid..........................pptx
Body fluid..........................pptxBody fluid..........................pptx
Body fluid..........................pptxDebdattaMandal5
 
renalfunctiontests-130723211756-phpapp01.pptx
renalfunctiontests-130723211756-phpapp01.pptxrenalfunctiontests-130723211756-phpapp01.pptx
renalfunctiontests-130723211756-phpapp01.pptxDebdattaMandal5
 
Imaging of the Renal System..........ppt
Imaging of the Renal System..........pptImaging of the Renal System..........ppt
Imaging of the Renal System..........pptDebdattaMandal5
 
DOC-20230308-WA0008.................pptx
DOC-20230308-WA0008.................pptxDOC-20230308-WA0008.................pptx
DOC-20230308-WA0008.................pptxDebdattaMandal5
 
labdiagnosisinrenaldiseases-copy-180611071550.pptx
labdiagnosisinrenaldiseases-copy-180611071550.pptxlabdiagnosisinrenaldiseases-copy-180611071550.pptx
labdiagnosisinrenaldiseases-copy-180611071550.pptxDebdattaMandal5
 
kidneydisorders-151105065618-lva1-app6892.ppt
kidneydisorders-151105065618-lva1-app6892.pptkidneydisorders-151105065618-lva1-app6892.ppt
kidneydisorders-151105065618-lva1-app6892.pptDebdattaMandal5
 
introductionadministrationmanagement-170719152235.pptx
introductionadministrationmanagement-170719152235.pptxintroductionadministrationmanagement-170719152235.pptx
introductionadministrationmanagement-170719152235.pptxDebdattaMandal5
 
multiple pregnancy....................pptx
multiple pregnancy....................pptxmultiple pregnancy....................pptx
multiple pregnancy....................pptxDebdattaMandal5
 
hypertensivedisordersofpregnancy-180930162838.pptx
hypertensivedisordersofpregnancy-180930162838.pptxhypertensivedisordersofpregnancy-180930162838.pptx
hypertensivedisordersofpregnancy-180930162838.pptxDebdattaMandal5
 
epidemiology-16062704353..........4.pptx
epidemiology-16062704353..........4.pptxepidemiology-16062704353..........4.pptx
epidemiology-16062704353..........4.pptxDebdattaMandal5
 
epidemiologypreventionandcontrolofplague-160627043327.pptx
epidemiologypreventionandcontrolofplague-160627043327.pptxepidemiologypreventionandcontrolofplague-160627043327.pptx
epidemiologypreventionandcontrolofplague-160627043327.pptxDebdattaMandal5
 
typhoidfeverppt-1812021.......24043.pptx
typhoidfeverppt-1812021.......24043.pptxtyphoidfeverppt-1812021.......24043.pptx
typhoidfeverppt-1812021.......24043.pptxDebdattaMandal5
 
tetanus-1205111525..28-phpapp02 (2).pptx
tetanus-1205111525..28-phpapp02 (2).pptxtetanus-1205111525..28-phpapp02 (2).pptx
tetanus-1205111525..28-phpapp02 (2).pptxDebdattaMandal5
 
poliomyelitis-1908102.........00943.pptx
poliomyelitis-1908102.........00943.pptxpoliomyelitis-1908102.........00943.pptx
poliomyelitis-1908102.........00943.pptxDebdattaMandal5
 
covidvaccines-210821171459...........pptx
covidvaccines-210821171459...........pptxcovidvaccines-210821171459...........pptx
covidvaccines-210821171459...........pptxDebdattaMandal5
 
covid-200424062237..................pptx
covid-200424062237..................pptxcovid-200424062237..................pptx
covid-200424062237..................pptxDebdattaMandal5
 
tetanus-120511152528-phpapp0. .pptx
tetanus-120511152528-phpapp0.        .pptxtetanus-120511152528-phpapp0.        .pptx
tetanus-120511152528-phpapp0. .pptxDebdattaMandal5
 
meningitis-170131181426888888888888.pptx
meningitis-170131181426888888888888.pptxmeningitis-170131181426888888888888.pptx
meningitis-170131181426888888888888.pptxDebdattaMandal5
 
whooping cough lecture...............ppt
whooping cough lecture...............pptwhooping cough lecture...............ppt
whooping cough lecture...............pptDebdattaMandal5
 
gasgangrene-200701120813............pptx
gasgangrene-200701120813............pptxgasgangrene-200701120813............pptx
gasgangrene-200701120813............pptxDebdattaMandal5
 

More from DebdattaMandal5 (20)

Body fluid..........................pptx
Body fluid..........................pptxBody fluid..........................pptx
Body fluid..........................pptx
 
renalfunctiontests-130723211756-phpapp01.pptx
renalfunctiontests-130723211756-phpapp01.pptxrenalfunctiontests-130723211756-phpapp01.pptx
renalfunctiontests-130723211756-phpapp01.pptx
 
Imaging of the Renal System..........ppt
Imaging of the Renal System..........pptImaging of the Renal System..........ppt
Imaging of the Renal System..........ppt
 
DOC-20230308-WA0008.................pptx
DOC-20230308-WA0008.................pptxDOC-20230308-WA0008.................pptx
DOC-20230308-WA0008.................pptx
 
labdiagnosisinrenaldiseases-copy-180611071550.pptx
labdiagnosisinrenaldiseases-copy-180611071550.pptxlabdiagnosisinrenaldiseases-copy-180611071550.pptx
labdiagnosisinrenaldiseases-copy-180611071550.pptx
 
kidneydisorders-151105065618-lva1-app6892.ppt
kidneydisorders-151105065618-lva1-app6892.pptkidneydisorders-151105065618-lva1-app6892.ppt
kidneydisorders-151105065618-lva1-app6892.ppt
 
introductionadministrationmanagement-170719152235.pptx
introductionadministrationmanagement-170719152235.pptxintroductionadministrationmanagement-170719152235.pptx
introductionadministrationmanagement-170719152235.pptx
 
multiple pregnancy....................pptx
multiple pregnancy....................pptxmultiple pregnancy....................pptx
multiple pregnancy....................pptx
 
hypertensivedisordersofpregnancy-180930162838.pptx
hypertensivedisordersofpregnancy-180930162838.pptxhypertensivedisordersofpregnancy-180930162838.pptx
hypertensivedisordersofpregnancy-180930162838.pptx
 
epidemiology-16062704353..........4.pptx
epidemiology-16062704353..........4.pptxepidemiology-16062704353..........4.pptx
epidemiology-16062704353..........4.pptx
 
epidemiologypreventionandcontrolofplague-160627043327.pptx
epidemiologypreventionandcontrolofplague-160627043327.pptxepidemiologypreventionandcontrolofplague-160627043327.pptx
epidemiologypreventionandcontrolofplague-160627043327.pptx
 
typhoidfeverppt-1812021.......24043.pptx
typhoidfeverppt-1812021.......24043.pptxtyphoidfeverppt-1812021.......24043.pptx
typhoidfeverppt-1812021.......24043.pptx
 
tetanus-1205111525..28-phpapp02 (2).pptx
tetanus-1205111525..28-phpapp02 (2).pptxtetanus-1205111525..28-phpapp02 (2).pptx
tetanus-1205111525..28-phpapp02 (2).pptx
 
poliomyelitis-1908102.........00943.pptx
poliomyelitis-1908102.........00943.pptxpoliomyelitis-1908102.........00943.pptx
poliomyelitis-1908102.........00943.pptx
 
covidvaccines-210821171459...........pptx
covidvaccines-210821171459...........pptxcovidvaccines-210821171459...........pptx
covidvaccines-210821171459...........pptx
 
covid-200424062237..................pptx
covid-200424062237..................pptxcovid-200424062237..................pptx
covid-200424062237..................pptx
 
tetanus-120511152528-phpapp0. .pptx
tetanus-120511152528-phpapp0.        .pptxtetanus-120511152528-phpapp0.        .pptx
tetanus-120511152528-phpapp0. .pptx
 
meningitis-170131181426888888888888.pptx
meningitis-170131181426888888888888.pptxmeningitis-170131181426888888888888.pptx
meningitis-170131181426888888888888.pptx
 
whooping cough lecture...............ppt
whooping cough lecture...............pptwhooping cough lecture...............ppt
whooping cough lecture...............ppt
 
gasgangrene-200701120813............pptx
gasgangrene-200701120813............pptxgasgangrene-200701120813............pptx
gasgangrene-200701120813............pptx
 

Recently uploaded

Historical philosophical, theoretical, and legal foundations of special and i...
Historical philosophical, theoretical, and legal foundations of special and i...Historical philosophical, theoretical, and legal foundations of special and i...
Historical philosophical, theoretical, and legal foundations of special and i...jaredbarbolino94
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceSamikshaHamane
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxAvyJaneVismanos
 
Crayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon ACrayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon AUnboundStockton
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxOH TEIK BIN
 
CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxJiesonDelaCerna
 
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...M56BOOKSTORE PRODUCT/SERVICE
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptxVS Mahajan Coaching Centre
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentInMediaRes1
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfSumit Tiwari
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Celine George
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
 
Capitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptxCapitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptxCapitolTechU
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersSabitha Banu
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfMahmoud M. Sallam
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Educationpboyjonauth
 

Recently uploaded (20)

Historical philosophical, theoretical, and legal foundations of special and i...
Historical philosophical, theoretical, and legal foundations of special and i...Historical philosophical, theoretical, and legal foundations of special and i...
Historical philosophical, theoretical, and legal foundations of special and i...
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in Pharmacovigilance
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptx
 
Crayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon ACrayon Activity Handout For the Crayon A
Crayon Activity Handout For the Crayon A
 
Model Call Girl in Bikash Puri Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Bikash Puri  Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Bikash Puri  Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Bikash Puri Delhi reach out to us at 🔝9953056974🔝
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptx
 
CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptx
 
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
KSHARA STURA .pptx---KSHARA KARMA THERAPY (CAUSTIC THERAPY)————IMP.OF KSHARA ...
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media Component
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
 
Capitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptxCapitol Tech U Doctoral Presentation - April 2024.pptx
Capitol Tech U Doctoral Presentation - April 2024.pptx
 
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
 
OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginners
 
ESSENTIAL of (CS/IT/IS) class 06 (database)
ESSENTIAL of (CS/IT/IS) class 06 (database)ESSENTIAL of (CS/IT/IS) class 06 (database)
ESSENTIAL of (CS/IT/IS) class 06 (database)
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdf
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Education
 

dengueepidemiology-200501161658.....pptx

  • 1. DENGUE EPIDEMIOLOGY Dr SEEMA VERMA Department of Community medicine PGIMS Rohtak Haryana INDIA
  • 2. DENGUE EPIDEMIOLOGY Introduction Epidemiological determinants Case definition Diagnosis and treatment Prevention and control Recent update & myths
  • 3. DENGUE EPIDEMIOLOGY Introduction Epidemiological determinants Case definition Diagnosis and treatment Prevention and control Recent update & myths
  • 4. INTRODUCTION  Most rapidly spreading mosquito-borne viral disease in the world.  The infection causes flu-like illness, ⚫ and occasionally develops into a potentially lethal complication – dengue shock syndrome.  Incidence of dengue has grown dramatically around the world in recent decades.  There is under-reporting & misclassification.
  • 5. INTRODUCTION  Before 1970, only 9 countries had experienced severe dengue epidemics.  Disease now endemic in more than 100 countries in the WHO regions of Africa, the Americas, the Eastern Mediterranean, South-East Asia and the Western Pacific.  The America, South-East Asia and Western Pacific regions are the most seriously affected.
  • 6. INTRODUCTION  Recent estimate – ⚫ 390 million dengue infections / year. ⚫ 96 million manifest clinically  The number of cases reported increased from 2.2 million in 2010 to 3.2 million in 2015.  Sharp increase in the number of cases reported in recent years. *World Health Organization. Dengue and severe dengue fact sheet. Geneva: WHO; 2016
  • 7. INTRODUCTION  South-East Asia region – divided into 3 categories • (Bangladesh,India, Indonesia,Maldives,Myanm ar,Sri Lanka,ThailandandTimor-Leste) • Majorpublichealthproblem; • Leadingcauseof hospitalizationanddeath amongchildren; • Hyperendemicity withall4serotypescirculating in urbanareas;and • Spreadingtoruralareas A
  • 8. INTRODUCTION  South-East Asia region – divided into 3 categories • (Bhutan,Nepal) • Endemicityuncertain; • Bhutanreportedfirst outbreakin2004;and • Nepalreported firstindigenouscasein2004. B • (DPRKorea) • Noevidenceofendemicity. C
  • 10. INTRODUCTION  Dengue now endemic in all states/UTs. After 1996, outbreaks upsurge recorded in 2003, 2005, 2008, 2010, 2012 and 2013.  During 2014, more than 40,000 cases and 137 deaths reported & case fatality rate 0.33%.  In 2015, 90,000 cases and 181 deaths reported. *DK Taneja’s Health Policies Programmes in India; 15th ed. 2017
  • 11. INTRODUCTION  In 2015, Delhi, recorded its worst outbreak since 2006 with over 15000 cases.  Disease is spreading to newer geographical areas every year.  Outbreaks have been reported from rural areas of Haryana, Maharashtra and Karnataka. *DK Taneja’s Health Policies Programmes in India; 15th ed. 2017
  • 12. INTRODUCTION (CASE TREND) 140000 120000 100000 80000 60000 40000 20000 0 200820092010 2011 201220132014201520162017 HARYANA INDIA DENGUE CASES YEAR CASES TILL 8TH OCTOBER 2017 (NVBDCP) 129161 78691 99913 75808 40571
  • 13. INTRODUCTION (MORTALITY TREND) 50 0 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 100 150 300 250 200 INDIA HARYANA DEATHS YEAR DATATILL 8TH OCTOBER 2017 (NVBDCP)
  • 14. INTRODUCTION  Dengue Problem Statement: ROHTAK 2017 *Till 15th Oct 2017
  • 15. INTRODUCTION  Dengue Problem Statement: Haryana & Rohtak 2017 800 600 400 200 0 Haryana Rohtak Rohtak Haryana 187 628 *TILL 15TH OCTOBER 2017 1 0
  • 17. DENGUE EPIDEMIOLOGY Introduction Epidemiological determinants Case definition Diagnosis and treatment Prevention and control Recent update & myths
  • 19. AGENT: DENGUE VIRUS  Arbovirus ss RNA virus ⚫ Genus Flavivirus ⚫ Family Flaviviraede.  Four serotypes: ⚫ DENV-1, DENV-2, DENV-3 and DENV-4.  Infection with one serotype confers ⚫ life long immunity to that virus serotype ⚫ and only for few months to other serotypes.
  • 20. AGENT: DENGUE VIRUS  All 4 serotypes are capable to produce DHF.  However, severity of the disease ascertained by ⚫ Serotype sequence & the strain which produces the secondary inf  DENV-1 DENV-2  DENV-3  DENV-2  DENV-4  DENV-2 - 500 fold - 150 fold - 50 fold risk of DHF risk of DHF.
  • 21. AGENT: DENGUE VIRUS WHY SECOND INFECTION IS MORE DANGEROUS?? SENSITIZATION OF IMMUNE SYSTEM PATIENT FIRST INFECTION SECOND INFECTION WITH DIFFERENT SEROTYPE IMMUNOLOGICAL CATASTROPHY
  • 22. VECTOR A aegypti is prevalent transmitter throughout India except Kerla where A albopictus is main vector for transmission.
  • 23. AEDES MOSQUITO  A small (5mm), black mosquito with white stripes.  Adult life span:15 days,  Flight range – 400 meters (average).
  • 24. AEDES MOSQUITO FEEDING HABITS:  Usually a Day biter,  preferably bites on the ankles and elbows. ⚫ (Peak : within 2 hours after dawn and before sunset.)  Is strongly anthropophilic.  Known to be a nervous feeder ⚫ it bites more than one host to complete one meal. ⚫ This feeding habit results in the generation of multiple cases and the clustering of dengue cases in the cities.
  • 25. AEDES MOSQUITO Life cycle: 7 – 10 days
  • 26. ENVIRONMENTAL FACTORS  The population of Aedes aegypti fluctuates with rainfall and water storage.  Its life span is influenced by ⚫ temperature (160C -300C) and humidity (60-80 %).  Even with a 20 increase in temperature, ⚫ The extrinsic incubation period of DENV will be shortened ⚫ and more infected mosquitoes are available for a longer duration. K Park , 24th ed; 2017,p 262
  • 27. ENVIRONMENTAL FACTORS  Unplanned urbanization raises the potential for the vector to breed at high level  Rural spread of the vector is a relatively recent occurrence with lifestyle changes coupled with development activities, improved transport system, deficient water management including improper water storage practices.
  • 29. ENVIRONMENTAL FACTORS  Seasonal trends of dengue cases in India 2010- 2013
  • 30. ENVIRONMENTAL FACTORS 140 120 100 80 60 40 20 0  Seasonal trends of dengue cases in Rohtak 2017 cases july aug sep oct cases CASES MONTHS *TILL OCTOBER 15TH 2017
  • 31. TRANSMISSION OF DISEASE  The Aedes mosquito becomes infective by feeding on a patient from the day before onset to the 5th day (viraemia stage) of illness.  After an extrinsic incubation period of 8 to 10 days, the mosquito becomes infective, and is able to transmit the infection.  Once the mosquito becomes infective, it remains so for life.  The genital tract of the mosquito gets infected and transovarian transmission of dengue virus occur. K.Parks.Park’s Textbook of Preventive and social medicine. Epidemiology of communicable diseases.24rd edition.Jabalpur india:M/s Banaridas Bhanot;2017:page-264
  • 33. DENGUE EPIDEMIOLOGY Introduction Epidemiological determinants Case definition Diagnosis and treatment Prevention and control Recent update & myths
  • 34. CASE DEFINITION  Suspected: ⚫ A case compatible with the clinical description.  Probable: ⚫ A case compatible with the clinical description with one or more of the following: ⚫ Supportive serology. ⚫ Occurrence at same location and time as other confirmed cases of dengue fever.  Confirmed: ⚫ A case compatible with the clinical description that is laboratory confirmed.
  • 35. D S S
  • 36. CLASSIFICATION Dengue virus infection Asymtomatic “ICE BERRG” Symptomatic Undifferentiated fever{ viral syndrome} Dengue fever Without haemorrhage With unusual haemorrhage Dengue haemorrhagic fever Unusual manifestation/ expanded dengue syndrome DHF 1 DHF 2 DHF3 DHF4 DSS
  • 38. DENGUE HAEMORRHAGIC FEVER (DHF)  A severe form of dengue fever.  The course of dengue illness can be divided into three phases- ⚫ febrile phase, ⚫ critical phase and ⚫ recovery phase,
  • 39.
  • 40. FEBRILE PHASE  Day 1 – 4  Fever with Positive tourniquet test
  • 41. TOURNIQUET TEST Goal of the test :-  Toasses fragility of capillary walls  Toidentify thrombocytopenia  In DHF grade 1, a positive tourniquet test serves as the only indicator of haemorrhagic tendency • ≥20 petechiae per 1 square inch.
  • 42. CRITICAL / HAEORRHAGIC PHASE  Whenthetemperaturedrops to37.5-38°Cor less,andremainsbelowthis level, usuallyon days4- 7ofillness,  Anincreasein capillary permeability in parallel with increasing haematocritlevels mayoccur.  This marksthebeginning ofthecritical phase.  Theperiodofclinicallysignificant plasmaleakage usuallylasts 24-48 hours.
  • 43. CRITICAL / HAEORRHAGIC PHASE  Shock occurs when a critical volume of plasma is lost through leakage.  It is often preceded by warning signs of ⚫ Abdominal pain or tenderness, ⚫ Persistent vomiting, ⚫ Clinical fluid accumulation, ⚫ Mucosal bleeding, ⚫ Lethargy, ⚫ Restlessness, ⚫ Liver enlargement more than 2 cm. and ⚫ Oliguria.
  • 44. CRITICAL / HAEORRHAGIC PHASE  With prolonged shock, the consequent organ hypoperfusion results in progressive organ impairment, metabolic acidosis and disseminated intravascular coagulation.  This in turn leads to severe haemorrhage causing the haematocrit to decrease in severe shock. Instead of the leukopenia usually seen during this phase of dengue, the total white cell count may increase in patients with severe bleeding.  In addition, severe organ impairment such as severe hepatitis, encephalitis or myocarditis and/or severe bleeding may also develop without obvious plasma leakage or shock.
  • 45. RECOVERY PHASE  After critical phase, 48-72 hours of reabsorption of extravascular fluid  Well-being, appetite improves  Bradycardia common  Hemodynamic status improves  GI symptoms abate  Blood counts normalize (RBC>WBC>Plt)  Diuresis occurs  Prolonged convalescence
  • 46. DENGUE EPIDEMIOLOGY Introduction Epidemiological determinants Case definition Diagnosis and treatment Prevention and control Recent update & myths
  • 47. RECOMMENDED TESTS  GOI recommends use of ELISA based antigen detection test (NS1) for diagnosing the cases from 1st day onwards.  Antibody detection test IgM Capture ELISA (MAC ELISA) for diagnosing the cases after 5th day of onset of disease for confirmation of Dengue infection
  • 48. RECOMMENDED TESTS  NVBDCP had been using MAC- ELISA for diagnosis of dengue infection in the network of Diagnostic Centers established/ identified in the Sentinel Surveillance Hospitals (SSHs) and Apex Referral Laboratories (ARLs) across the country.
  • 49. RECOMMENDED TESTS IgG (FIRST) IgG (SECOND) IgM NS-1 VIRUS
  • 50. RAPID TEST COMBO KIT  Most of the studies have shown that detection of both the NS1 Antigen and the anti-dengueIgm together yields satisfactory clinical results, instead of sole NS1 antigen detection.
  • 51. DIAGNOSTIC KIT USED IN PGIMS ROHTAK For NS-1 Antigen detection ( <5days)
  • 52. DIAGNOSTIC KIT USED IN PGIMS ROHTAK IgM capture ELISA ( >5days)
  • 53. SENTINAL SURVEILLANCE HOSPITALS FOR DENGUE IN HARYANA 2016 1 B.K. Hospital, Faridabad 2 General Hospital, Ambala 3 State Bacteriological Laboratory,Karnal 4 General Hospital, Gurgaon 5 General Hospital, Panchkula 6 Medical College, Agroha 7 Civil Hospital, Hissar 8 PGIMS,Rohtak 9 District Hospital, Kaithal 10 District Hospital, Kurukshetra 11 Mukandi lal Hospital,Yamuna Nagar 12 Civil Hospital, Sonipat 13 General Hospital, Palwal 14 Civil Hospital, Bahadurgarh (Jhajjar) 15 District Hospital, Sirsa 16 District Hospital, Bhiwani 17 District Hospital, Fatehbaad 18 District Hospital, Jind 19 District Hospital, Panipat 20 Civil Hospital, Mandi Khera (Mewat) 21 Civil Hospital, Narnual 22 Civil Hospital, Rewari
  • 54. APEX REFERAL LABORATORIES National Institute of Virology (ICMR), Pune 2. National Center for Disease Control (former NICD), Delhi 3. National Institute of Mental Health & Neuro-Sciences, Bangalore 4. Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow 5. Post- Graduate Institute of Medical Sciences(PGIMER), ICMR, Chandigarh 6. All India Institute of Medical Sciences, Delhi 7. ICMR Virus Unit, National Institute of Cholera & Enteric Diseases, Kolkata. 8. Regional Medical Research Centre, (ICMR),Dibrugarh, Assam 9. King’s Institute of Preventive Medicine (ICMR), Chennai 10. Institute of Preventive Medicine, Hyderabad 11. B J Medical College (ICMR) , Ahmedabad 12. State Public Health Laboratory, Thiruvananthapuram, Kerala 13. Defence Research Development and Establishment, Gwalior, Madhya Pradesh 14. Nati onal Institute for Research in Tribal Health (NIRTH) (Former RMRCT), ICMR, Jabalpur, Madhya Pradesh 15. Regional Medical Research Centre, (ICMR), Bhubaneswar, Odisha 16. Andhra Medical College, Visakhapatnam
  • 55. MANAGEMENT OF DENGUE FEVER MANAGED AT HOME BED REST COLD/TEPID SPONGING PARACETAMOL WARNING SIGNS SHOULD BE EXPLAINED ADVISED TO REPORT TO HOSPITAL IF WARNING SIGNS APPEAR
  • 56. WARNING SIGNS RECURRET VOMITING BLEEDING FROM DIFFERENT SITES:  GUM BLEEDING  BLOOD IN SPUTUM  BLOOD IN VOMIT OR STOOL  INCREASED MENSTRUAL FLOW ABDOMINAL PAIN OR DISCOMFORT COLD CLAMY SKIN PALPITAION BREATHLESSNESS
  • 57. MANAGEMENT OF DHF ALL CASES TO BE ADMITTED ENCOURAGE ORAL FLUIDS:ORS,JUICES START I.V. FLUIDS PARACETAMOL DAILY HEMATOCRIT DETERMINATION MONITOR URINE OUTPUT, B.P. AND OTHER VITAL SIGNS Platelet concentrate :  if the platelet count is < 50,000 / mm3 with bleeding.  In the absence of bleeding :counts <10,000/ mm3
  • 58. MANAGEMENT OF DSS All of the following 6 criteria must be met before a patient is discharged from the hospital : 1. Visible improvement in clinical picture 2.Absence of fever for 24 hours & return of appetite 3.Three days after recovery from shock 4.Stable hematocrit 5.Platelet count greater than 50,000/mm3 and rising 6.No respiratory distress
  • 59. DENGUE EPIDEMIOLOGY Introduction Epidemiological determinants Case definition Diagnosis and treatment Prevention and control Recent update & myths
  • 60. GLOBAL STRATEGY FOR DENGUE PREVENTION AND CONTROL, 2012–2020  GOAL: To reduce the burden of dengue  OBJECTIVES: (using 2010 as the baseline).  To reduce mortality from dengue by at least 50% by 2020.  To reduce morbidity from dengue by at least 25% by 2020  To estimate the true burden of dengue till 2015. WHO (2012), Global Strategy for Dengue Prevention and Control,2012-2020.
  • 61. EPIDEMIOLOGICAL SURVEILLANCE Routine surveillance:  Passive  Active Proactive surveillance:  serological surveillance designed to monitor dengue virus transmission, especially during inter-epidemic periods and provide information on: ⚫ Where transmission is occurring, ⚫ What virus serotype or serotypes are involved and ⚫ Which type of illness is associated with the dengue
  • 62. EPIDEMIOLOGICAL SURVEILLANCE Reporting :  During transmission period ⚫ (monsoon and post Monsoon reporting will be on ⚫ daily basis by email or by fax.  In non or low transmission period ⚫ reporting will be on weekly basis. ⚫ Report of the previous week (Monday to Saturday) should be compiled by the States and send to NVBDCP by every Monday.
  • 64. EPIDEMIOLOGICAL SURVEILLANCE The larval indices used to determine the intensity of dengue vector are:  House Index: ⚫ Percentage of houses positive for larvae of A aegypti ⚫ (> 10% - high risk of transmission)  Breteau Index: ⚫ Number of positive containers for A aegypti larvae per 100 houses. ⚫ (> 50% - high risk of transmission)
  • 65. ENVIRONMENTAL CONTROL  Don’t allow water to remain stagnant in and around your house.  Fill the ditches.  Clean the blocked drains.  Empty the room air coolers and flower vases completely at least once in seven days and let them dry.  Dispose off old containers, tins and tyres etc. properly.  Keep the water tanks and water containers tightly covered so that the mosquitoes can not enter them and start breeding.
  • 66. ENVIRONMENTAL CONTROL  Wherever it is not possible to completely drain the water off from room cooler, water tanks etc., it is advised to put about two tablespoons (30 ml.) of petrol or kerosene oil into them for each 100 litres of water.  This will prevent mosquito breeding.  Repeat it every week.  Keep the surroundings of your house clean.  Don’t allow wild herbs etc. to grow around your house. They act as hiding and resting places for mosquitoes.
  • 67. PERSONAL PROTECTION MEASURES Protective clothing mats coils Insecticide treated nets Permethrin treated clothing Repellent sprays (DEET) Electric Raquete
  • 68. CHEMICAL CONTROL LARVICIDAL ADULTICIDAL RESIDUAL TREATMENT SPACE SPRAY OUTDOOR INDOOR COLD AEROSOL THERMAL FOGGING PYRETHRUM
  • 69. INDOOR SPACE SPRAYING  Commercial formulation of 2% pyrethrum (deltamethrin) extract is diluted with kerosene in the ratio one part of 2% pyrethrum extract with 19 parts of kerosene (volume/volume).  One liter of ‘formulation is sufficient to cover 20 households, each household having 100 cubic meters of indoor space.
  • 70. OUTDOOR SPACE SPRAYING  Usually carried out in early morning or late afternoon  For narrow roads: the spray should be directed backwards from the vehicle.  For wide roads: the spray should be directed at a right angle (downward) to the road. 1. Ultra Low Volume (ULV) Spray(cold fog): ⚫ Malathion TECHNICAL is the insecticide used for this purpose. ⚫ Remain suspended in air and driven under the influence of wind. ⚫ Since no diluent is used, the technique is more cost- effective than thermal fogging. ⚫ But it does not generate a visible fog.
  • 71. OUTDOOR SPACE SPRAYING 2. Thermal Fogging ⚫ Water based ⚫ Oil based(m/c used)  Technique is based on the principle that insecticide is vaporized, which condenses to form a fine cloud of droplets on contact with cooler air when it comes out of the machine.  Insecticide of choice for fogging is malathion/pyrethrin.
  • 72. LARVICIDES  Cycle : 2-3rounds /year  Both internal and external walls of container should be sprayed and up to 60cm of height. LARVICIDES FOR POTABLE WATER FOR NON-POTABLE WATER TEMEPHOS (1mg/L) METHOPRENE(1mg/l) TEMEPHOS (1mg/L) Bacillus thuringiensis israelensis (bio-chemical)
  • 73. BIOLOGICAL CONTROL Larvivorous Fish  Advantages  Environmental friendly  Easy to introduce  Self propagating & self sustainable  User friendly  Helps build community participation & intersectoral collaboration  Cost-Effective - no recurrent costs Gambusia affinis Lebister reticularis
  • 74. BIOLOGICAL CONTROL Larvivorous Fish  Limitations  Extremes of temperatures and pollution  Suitable for some types of breeding sources only  Needs proper planning with mapping of breeding sources & promotional efforts Biolarvicide: Bacillus thuringiensis iserailensis (Bti)-Endotoxin : 2.5% suspension, 1 lit/50 m2, once every 2 Aphanius dispar
  • 75. 4s VECTOR CONTROL SEARCH AND DESTROY SELF-PROTECTION MEASURES SEEK EARLY CONSULTATION SAY NO TO INDISCRIMINATE FOGGING  HEALTH EDUCATION 🞭 Impart knowledge to common people regarding the disease and vector through various media sources like T.v., Radio,Cinema slides, PAMPLETS etc.  COMMUNITY PARTICIPATION Sensitizing and involving the community for detection of Aedes breeding places and their elimination
  • 76. LEGISLATION 1. Model civic byelaws: fine/punishment is imparted, if breeding is detected. In cities Rohtak, Delhi, Mumbai, Chandigarh. 2. Building Construction Regulation Act: In Mumbai, prior to any construction activity, the owners/builders deposit a fee for controlling mosquitogenic conditions at site by the Municipal Corporation. 3. Environmental Health Act 4. Health Impact Assessments
  • 77. OUTBREAK RESPONSE Rapid response team:  Aim to undertake urgent epidemiological investigations and provide on the spot technical guidance required and logistic support. Rapid response team: Rohtak  District malaria officer  D.F.W.O  SMO  Epidemiologist  MO CH (Med)  MO CH (Micro)
  • 78. DENGUE EPIDEMIOLOGY Introduction Epidemiological determinants Case definition Diagnosis and treatment Prevention and control Recent update & myths
  • 79. DENGUE VACCINE  Currently, there is no vaccine available in India to protect against dengue.  In recent years the development of dengue vaccines has accelerated dramatically.  Today, several vaccines are in various stages of advanced development, with clinical trials currently underway on five candidate vaccines. http://www.denguevaccines.org/why-a-vaccine
  • 80. http://www.denguevaccines.org/why-a-vaccine A live, attenuated, tetravalent dengue vaccine (CYD-TDV) candidate, containing four recombinant dengue viruses (CYD1- 4)
  • 81.  The fifth variant DENV-5 has been isolated in October 2013.  The likely cause of emergence of the new serotype could be genetic recombination, natural selection.  GM (Genetically modified Mosquito) – Male sterile mosquitoes are released in environment so as to mate with wild females and produce sterile eggs. It is still in experimental stage. http://nvbdcp.gov.in/Doc/Dengue-FAQ-2015.pdf
  • 82. Spread the dengue prevention message to others… Let your family, friends and neighbours know about the dangers of breeding Mozzies!! THANK YOU …